Search
Lineage Cell Therapeutics Inc
LCTXAdd to Watchlist
1.350USD
+0.045+3.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
336.55MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Lineage Cell Therapeutics Inc is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 3.00, with a high of 9.00 and a low of 2.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
5.500
Target Price
+323.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Lineage Cell Therapeutics Inc
LCTX
7
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Lineage Cell Therapeutics Inc's expected revenue for the next quarter?
Lineage Cell Therapeutics Inc's expected revenue is 4.04M.
What is Lineage Cell Therapeutics Inc's price target?
Analysts forecast that Lineage Cell Therapeutics Inc's price target is USD 3.00, with the highest forecast at USD 9.00 and the lowest forecast at USD 2.00.
What is the analyst rating for Lineage Cell Therapeutics Inc?
Based on the ratings of Lineage Cell Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.